Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions.
Coller
B S
BS
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. bcoller@smtplink.mssm.edu
D000077284:Abciximab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D001792:Blood Platelets / Q000502:physiology*; D002450:Cell Communication; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism*; D007962:Leukocytes / Q000502:physiology*; D016177:Macrophage-1 Antigen / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D019030:Receptors, Vitronectin / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D016177:Macrophage-1 Antigen; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019030:Receptors, Vitronectin; D000077284:Abciximab